SMYD2 and breast cancer: A correlation analysis between the expression of SMYD2 and candidate substrates in metastatic vs non-metastatic breast cancer identified BCAR3 as the strongest positive hit in metastatic breast cancer (Fig. 2b; Supplementary Table S3).